Streetbeat News

Analyst Ratings

GMAB

BTIG analyst Kaveri Pohlman maintains a Buy rating on Genmab (NASDAQ:GMAB) and raises the price target from $44 to $46.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 3:43 pm

IMVT

Immunovant's stock has been upgraded from Neutral to Buy by UBS, with the price target raised from $18 to $55. This has resulted in Immunovant shares trading higher.

Portfolio Pulse from Bill Haddad

October 13, 2023 | 3:42 pm

PM

Jefferies analyst Owen Bennett maintains a Buy rating on Philip Morris Intl (NYSE:PM) but lowers the price target from $111 to $105.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 3:38 pm

TSX:TOY

RBC Capital analyst Sabahat Khan maintains an Outperform rating on Spin Master and raises the price target from C$49 to C$51.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 3:37 pm

TSX:MTY

RBC Capital analyst Sabahat Khan maintains a 'Sector Perform' rating on MTY Food Gr and lowers the price target from C$71 to C$66.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 3:34 pm

TSX:BTE

RBC Capital analyst Greg Pardy maintains an Outperform rating on Baytex Energy (TSX:BTE) and announces a price target of C$8.5.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 3:32 pm

BTCUSD

ETHUSD

Crypto analyst Jason Pizzino warns of potential steep declines in altcoins if Bitcoin's value drops to test $26,700 and potentially even $24,900. He suggests that such a scenario would have dire consequences on altcoins. While Ethereum is a separate concern, Pizzino highlights its struggling state amidst the current market volatility. He suggests that if Bitcoin breaches its $26,700 support, altcoins will continue to struggle and might see even steeper declines if Bitcoin hits the $25,000 mark.

Portfolio Pulse from Murtuza Merchant

October 13, 2023 | 3:30 pm

ATXS

Wedbush analyst Laura Chico maintains an Outperform rating on Astria Therapeutics (NASDAQ:ATXS) but lowers the price target from $25 to $18.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 3:22 pm

LC

Wedbush analyst David Chiaverini maintains an Outperform rating on LendingClub (NYSE:LC) and announces a $9 price target.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 3:19 pm

BNTX

BioNTech Inc.'s stock is currently trading at $108.00, after a 0.83% drop. Over the past month, the stock fell by 5.68%, and in the past year, by 23.25%. The company's P/E ratio is 5.68, lower than the Biotechnology industry average of 40.45, which could indicate that the stock is undervalued or that shareholders do not expect the stock to perform better in the future.

Portfolio Pulse from Benzinga Insights

October 13, 2023 | 3:15 pm